Paragon Capital Management LLC purchased a new position in shares of Chemed Co. (NYSE:CHE) in the first quarter, HoldingsChannel reports. The firm purchased 125 shares of the company’s stock, valued at approximately $40,000.
Other large investors have also modified their holdings of the company. Hollencrest Capital Management raised its position in Chemed by 5.9% during the 1st quarter. Hollencrest Capital Management now owns 768 shares of the company’s stock worth $246,000 after buying an additional 43 shares during the last quarter. First Hawaiian Bank increased its holdings in shares of Chemed by 21.3% in the 4th quarter. First Hawaiian Bank now owns 290 shares of the company’s stock valued at $82,000 after purchasing an additional 51 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Chemed by 0.6% in the 4th quarter. Arizona State Retirement System now owns 11,492 shares of the company’s stock valued at $3,255,000 after purchasing an additional 68 shares in the last quarter. Bremer Trust National Association purchased a new position in shares of Chemed in the 4th quarter valued at about $25,000. Finally, Captrust Financial Advisors increased its holdings in shares of Chemed by 32.3% in the 4th quarter. Captrust Financial Advisors now owns 373 shares of the company’s stock valued at $106,000 after purchasing an additional 91 shares in the last quarter. Hedge funds and other institutional investors own 88.29% of the company’s stock.
Shares of CHE traded up $2.99 during trading hours on Monday, reaching $327.44. The company had a trading volume of 63,246 shares, compared to its average volume of 130,878. The company has a quick ratio of 0.80, a current ratio of 0.83 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $5.18 billion, a PE ratio of 27.45, a P/E/G ratio of 2.87 and a beta of 1.20. Chemed Co. has a 12-month low of $260.03 and a 12-month high of $335.99.
Chemed (NYSE:CHE) last announced its quarterly earnings results on Wednesday, February 20th. The company reported $3.35 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.27 by $0.08. The business had revenue of $457.51 million during the quarter, compared to the consensus estimate of $460.50 million. Chemed had a net margin of 11.53% and a return on equity of 36.06%. The business’s revenue was up 6.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.32 EPS. On average, research analysts anticipate that Chemed Co. will post 12.77 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, March 22nd. Shareholders of record on Monday, March 4th were issued a dividend of $0.30 per share. The ex-dividend date of this dividend was Friday, March 1st. This represents a $1.20 annualized dividend and a yield of 0.37%. Chemed’s dividend payout ratio (DPR) is currently 10.06%.
In other Chemed news, CEO Kevin J. Mcnamara sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $323.47, for a total transaction of $1,617,350.00. Following the completion of the transaction, the chief executive officer now directly owns 155,094 shares in the company, valued at approximately $50,168,256.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director George J. Walsh III sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $328.07, for a total transaction of $328,070.00. Following the transaction, the director now owns 7,663 shares of the company’s stock, valued at $2,514,000.41. The disclosure for this sale can be found here. Insiders have sold a total of 14,599 shares of company stock valued at $4,754,381 over the last 90 days. 4.82% of the stock is currently owned by insiders.
CHE has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of Chemed from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Royal Bank of Canada increased their price target on shares of Chemed from $313.00 to $318.00 and gave the company a “sector perform” rating in a report on Monday, February 25th.
TRADEMARK VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2019/04/15/paragon-capital-management-llc-purchases-new-position-in-chemed-co-che.html.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Recommended Story: How do investors use RSI to grade stocks?
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.